Cargando…
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200228/ https://www.ncbi.nlm.nih.gov/pubmed/37092225 http://dx.doi.org/10.3233/JAD-230032 |
_version_ | 1785045096685633536 |
---|---|
author | Chen, Charles D. Ponisio, Maria Rosana Lang, Jordan A. Flores, Shaney Schindler, Suzanne E. Fagan, Anne M. Morris, John C. Benzinger, Tammie L.S. |
author_facet | Chen, Charles D. Ponisio, Maria Rosana Lang, Jordan A. Flores, Shaney Schindler, Suzanne E. Fagan, Anne M. Morris, John C. Benzinger, Tammie L.S. |
author_sort | Chen, Charles D. |
collection | PubMed |
description | BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET differ from how (18)F-flortaucipir PET has been measured in research settings using standardized uptake value ratios (SUVRs). How visual interpretation relates to (18)F-flortaucipir PET SUVR, cerebrospinal fluid (CSF) biomarkers, or longitudinal clinical assessment is not well understood. OBJECTIVE: We compare various diagnostic methods in participants enrolled in longitudinal observational studies of aging and memory (n = 189, 23 were cognitively impaired). METHODS: Participants had tau PET, Aβ PET, MRI, and clinical and cognitive evaluation within 18 months (n = 189); the majority (n = 144) also underwent lumbar puncture. Two radiologists followed manufacturer’s guidelines for (18)F-flortaucipir PET visual interpretation. RESULTS: Visual interpretation had high agreement with SUVR (98.4%)and moderate agreement with CSF p-tau181 (86.1%). Two participants demonstrated (18)F-flortaucipir uptake from meningiomas. Visual interpretation could not predict follow-up clinical assessment in 9.52% of cases. CONCLUSION: Visual interpretation was highly consistent with SUVR (discordant participants had hemorrhagic infarcts or occipital-predominant AD NFT deposition) and moderately consistent with CSF p-tau181 (discordant participants had AD pathophysiology not detectable on tau PET). However, close association between AD NFT deposition and clinical onset in group-level studies does not necessarily hold at the individual level, with discrepancies arising from atypical AD, vascular dementia, or frontotemporal dementia. A better understanding of relationships across imaging, CSF biomarkers, and clinical assessment is needed to provide appropriate diagnoses for these individuals. |
format | Online Article Text |
id | pubmed-10200228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102002282023-05-22 Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment Chen, Charles D. Ponisio, Maria Rosana Lang, Jordan A. Flores, Shaney Schindler, Suzanne E. Fagan, Anne M. Morris, John C. Benzinger, Tammie L.S. J Alzheimers Dis Research Article BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET differ from how (18)F-flortaucipir PET has been measured in research settings using standardized uptake value ratios (SUVRs). How visual interpretation relates to (18)F-flortaucipir PET SUVR, cerebrospinal fluid (CSF) biomarkers, or longitudinal clinical assessment is not well understood. OBJECTIVE: We compare various diagnostic methods in participants enrolled in longitudinal observational studies of aging and memory (n = 189, 23 were cognitively impaired). METHODS: Participants had tau PET, Aβ PET, MRI, and clinical and cognitive evaluation within 18 months (n = 189); the majority (n = 144) also underwent lumbar puncture. Two radiologists followed manufacturer’s guidelines for (18)F-flortaucipir PET visual interpretation. RESULTS: Visual interpretation had high agreement with SUVR (98.4%)and moderate agreement with CSF p-tau181 (86.1%). Two participants demonstrated (18)F-flortaucipir uptake from meningiomas. Visual interpretation could not predict follow-up clinical assessment in 9.52% of cases. CONCLUSION: Visual interpretation was highly consistent with SUVR (discordant participants had hemorrhagic infarcts or occipital-predominant AD NFT deposition) and moderately consistent with CSF p-tau181 (discordant participants had AD pathophysiology not detectable on tau PET). However, close association between AD NFT deposition and clinical onset in group-level studies does not necessarily hold at the individual level, with discrepancies arising from atypical AD, vascular dementia, or frontotemporal dementia. A better understanding of relationships across imaging, CSF biomarkers, and clinical assessment is needed to provide appropriate diagnoses for these individuals. IOS Press 2023-05-16 /pmc/articles/PMC10200228/ /pubmed/37092225 http://dx.doi.org/10.3233/JAD-230032 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Chen, Charles D. Ponisio, Maria Rosana Lang, Jordan A. Flores, Shaney Schindler, Suzanne E. Fagan, Anne M. Morris, John C. Benzinger, Tammie L.S. Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title | Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title_full | Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title_fullStr | Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title_full_unstemmed | Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title_short | Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment |
title_sort | comparing tau pet visual interpretation with tau pet quantification, cerebrospinal fluid biomarkers, and longitudinal clinical assessment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200228/ https://www.ncbi.nlm.nih.gov/pubmed/37092225 http://dx.doi.org/10.3233/JAD-230032 |
work_keys_str_mv | AT chencharlesd comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT ponisiomariarosana comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT langjordana comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT floresshaney comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT schindlersuzannee comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT faganannem comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT morrisjohnc comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment AT benzingertammiels comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment |